139 related articles for article (PubMed ID: 37592092)
1. Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
Isfort S; Manz K; Teichmann LL; Crysandt M; Burchert A; Hochhaus A; Saussele S; Kiani A; Göthert JR; Illmer T; Schafhausen P; Al-Ali HK; Stegelmann F; Hänel M; Pfeiffer T; Giagounidis A; Franke GN; Koschmieder S; Fabarius A; Ernst T; Warnken-Uhlich M; Wolber U; Kohn D; Pfirrmann M; Wolf D; Brümmendorf TH;
Ann Hematol; 2023 Oct; 102(10):2741-2752. PubMed ID: 37592092
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
García-Gutiérrez V; Milojkovic D; Hernandez-Boluda JC; Claudiani S; Martin Mateos ML; Casado-Montero LF; González G; Jimenez-Velasco A; Boque C; Martinez-Trillos A; Vázquez IM; Payer ÁR; Senín A; Amustio Díez E; García AB; Carrascosa GB; Ortí G; Ruiz BC; Fernández MÁ; Del Carmen García Garay M; Giraldo P; Guinea JM; De Las Heras Rodríguez N; Hernán N; Pérez AI; Piris-Villaespesa M; Lorenzo JLL; Martí-Tutusaus JMM; Vallansot RO; Ortega Rivas F; Puerta JM; Ramirez MJ; Romero E; Romo A; Rosell A; Saavedra SS; Sebrango A; Tallon J; Valencia S; Portero A; Steegmann JL;
Ann Hematol; 2019 Feb; 98(2):321-330. PubMed ID: 30446802
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia.
Hino M; Matsumura I; Fujisawa S; Ishizawa K; Ono T; Sakaida E; Sekiguchi N; Tanetsugu Y; Fukuhara K; Ohkura M; Koide Y; Takahashi N
Int J Hematol; 2020 Jul; 112(1):24-32. PubMed ID: 32279228
[TBL] [Abstract][Full Text] [Related]
4. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A; Fogliatto LM; Kim DDH; le Coutre P; Saussele S; Annunziata M; Hughes TP; Chaudhri N; Sasaki K; Chee L; García-Gutiérrez V; Cortes JE; Aimone P; Allepuz A; Quenet S; Bédoucha V; Hochhaus A
Blood; 2021 Nov; 138(21):2031-2041. PubMed ID: 34407542
[TBL] [Abstract][Full Text] [Related]
5. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
Cortes JE; Kim DW; Kantarjian HM; Brümmendorf TH; Dyagil I; Griskevicius L; Malhotra H; Powell C; Gogat K; Countouriotis AM; Gambacorti-Passerini C
J Clin Oncol; 2012 Oct; 30(28):3486-92. PubMed ID: 22949154
[TBL] [Abstract][Full Text] [Related]
6. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH
Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529
[TBL] [Abstract][Full Text] [Related]
8. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
Gambacorti-Passerini C; Brümmendorf TH; Kim DW; Turkina AG; Masszi T; Assouline S; Durrant S; Kantarjian HM; Khoury HJ; Zaritskey A; Shen ZX; Jin J; Vellenga E; Pasquini R; Mathews V; Cervantes F; Besson N; Turnbull K; Leip E; Kelly V; Cortes JE
Am J Hematol; 2014 Jul; 89(7):732-42. PubMed ID: 24711212
[TBL] [Abstract][Full Text] [Related]
9. Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia.
Garrett M; Knight B; Cortes JE; Deininger MW
Cancer Med; 2023 Sep; 12(17):17981-17992. PubMed ID: 37553873
[TBL] [Abstract][Full Text] [Related]
10. Bosutinib for the treatment of chronic myeloid leukemia.
Doan V; Wang A; Prescott H
Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
[TBL] [Abstract][Full Text] [Related]
11. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Dyagil I; Glushko N; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Reilly L; Jeynes-Ellis A; Leip E; Bardy-Bouxin N; Hochhaus A; Brümmendorf TH
J Clin Oncol; 2018 Jan; 36(3):231-237. PubMed ID: 29091516
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
Gambacorti-Passerini C; Cortes JE; Lipton JH; Kantarjian HM; Kim DW; Schafhausen P; Crescenzo R; Bardy-Bouxin N; Shapiro M; Noonan K; Leip E; DeAnnuntis L; Brümmendorf TH; Khoury HJ
Haematologica; 2018 Aug; 103(8):1298-1307. PubMed ID: 29773593
[TBL] [Abstract][Full Text] [Related]
13. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review.
Cortes JE; Apperley JF; DeAngelo DJ; Deininger MW; Kota VK; Rousselot P; Gambacorti-Passerini C
J Hematol Oncol; 2018 Dec; 11(1):143. PubMed ID: 30587215
[TBL] [Abstract][Full Text] [Related]
14. Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.
Levy MY; McGarry LJ; Huang H; Lustgarten S; Chiroli S; Iannazzo S
Curr Med Res Opin; 2019 Mar; 35(3):479-487. PubMed ID: 30086654
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Cortes JE; Kantarjian HM; Brümmendorf TH; Kim DW; Turkina AG; Shen ZX; Pasquini R; Khoury HJ; Arkin S; Volkert A; Besson N; Abbas R; Wang J; Leip E; Gambacorti-Passerini C
Blood; 2011 Oct; 118(17):4567-76. PubMed ID: 21865346
[TBL] [Abstract][Full Text] [Related]
16. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
Kantarjian HM; Cortes JE; Kim DW; Khoury HJ; Brümmendorf TH; Porkka K; Martinelli G; Durrant S; Leip E; Kelly V; Turnbull K; Besson N; Gambacorti-Passerini C
Blood; 2014 Feb; 123(9):1309-18. PubMed ID: 24345751
[TBL] [Abstract][Full Text] [Related]
17. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
Yuda J; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Matsumura I; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Allepuz A; Minami Y
Cancer Med; 2023 Feb; 12(3):2990-2998. PubMed ID: 36168187
[TBL] [Abstract][Full Text] [Related]
18. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Hill BG; Kota VK; Khoury HJ
Expert Rev Anticancer Ther; 2014 Jul; 14(7):765-70. PubMed ID: 24875651
[TBL] [Abstract][Full Text] [Related]
19. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
Isfort S; Keller-v Amsberg G; Schafhausen P; Koschmieder S; Brümmendorf TH
Recent Results Cancer Res; 2014; 201():81-97. PubMed ID: 24756786
[TBL] [Abstract][Full Text] [Related]
20. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Hochhaus A; Réa D; Boquimpani C; Minami Y; Cortes JE; Hughes TP; Apperley JF; Lomaia E; Voloshin S; Turkina A; Kim DW; Abdo A; Fogliatto LM; le Coutre P; Sasaki K; Kim DDH; Saussele S; Annunziata M; Chaudhri N; Chee L; García-Gutiérrez V; Kapoor S; Allepuz A; Quenet S; Bédoucha V; Mauro MJ
Leukemia; 2023 Mar; 37(3):617-626. PubMed ID: 36717654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
